

MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

BRIMONIDINE TARTRATE 3MG/G GEL (e.g. MIRVASO®):

BLACK: NOT RECOMMENDED FOR PRESCRIBING IN PRIMARY, COMMUNITY OR SECONDARY CARE

Mid and South Essex CCGs do not support the prescribing of brimonidine tartrate 3mg/g gel (e.g. Mirvaso®) as it is considered to be a cosmetic product.

Rosacea is a chronic relapsing disease of facial skin, characterised by recurrent episodes of facial flushing, persistent erythema, telangiectasia (fine, dilated blood vessels), papules and pustules. For the symptoms of flushing and erythema (without papules and pustules) management generally consists of lifestyle advice, including applying sunscreen and avoiding trigger factors when practical. Brimonidine tartrate gel is the first medicinal product to be approved for the symptomatic treatment of facial erythema of rosacea.

Brimonidine tartrate 3mg/g gel is licensed for symptomatic treatment of facial erythema of rosacea in adult patients. It achieves this by direct vasoconstriction of superficial peripheral blood vessels.

Its use is considered to be cosmetic in nature and therefore brimonidine tartrate 3mg/g gel (e.g. Mirvaso®) is **not** recommended for prescribing.

For further information please refer to the East of England Priorities Advisory Committee guidance statement January 2015: [PAC – Brimonidine tartrate gel](#).

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

References	East of England Priorities Advisory Committee Guidance Statement: Brimonidine tartrate gel (Mirvaso®) for the treatment of facial erythema – evidence review: https://www.prescgipp.info/media/3255/brimonidine-tartrate-gel-mirvaso-for-the-treatment-of-facial-erythema.zip
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	MSEMOC; MSE Joint Committee
Date Approved	December 2020; January 2021
Review Date	December 2025 or sooner if subject to any new updates nationally